Free Trial
NASDAQ:ALEC

Alector Q1 2024 Earnings Report

Alector logo
$1.48 +0.10 (+7.25%)
Closing price 04:00 PM Eastern
Extended Trading
$1.38 -0.10 (-6.69%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alector EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Alector Revenue Results

Actual Revenue
$15.89 million
Expected Revenue
$14.63 million
Beat/Miss
Beat by +$1.26 million
YoY Revenue Growth
N/A

Alector Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Wednesday, May 8, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Alector's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Alector Earnings Headlines

Top Penny Stocks To Watch In May 2025
Why July 22nd Could Mean Big Changes for Social Security
In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Social Security — and his plan is set to roll out July 22. What's coming next isn't about trimming waste.
See More Alector Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alector? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alector and other key companies, straight to your email.

About Alector

Alector (NASDAQ:ALEC), a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

View Alector Profile

More Earnings Resources from MarketBeat